Abstract
Adverse reactions to bare metal stent implantation include stent thrombosis and restenosis. Although thrombosis in bare metal stents seems mainly to be affected by procedural factors, restenosis is a more complex procedure involving mechanisms of tissue repair after vessel injury occurring during implantation. This procedure includes early platelet and leukocyte invasion, followed by smooth muscle cell proliferation, as well as further inflammatory cell recruitment mediated by expression of chemokines and leukocyte activation at the site of the injury. In this report, we will focus on the role of inflammation in the development of in-stent restenosis in bare metal stents. In particular, we will describe the pathologic evidence implicating inflammatory cell involvement in the development of restenosis in animal and human models; we will analyze the molecular mechanisms linking inflammation with restenosis; and will review the association of pre-existing or procedure-induced systemic inflammation with adverse reactions at follow-up.
Keywords: Bare metal stents, restenosis, pathology, inflammation, biomarkers, CRP, interleukins, monocytes.
Current Vascular Pharmacology
Title:Inflammatory Mechanisms of Adverse Reactions to BMS
Volume: 11 Issue: 4
Author(s): Konstantinos Toutouzas, Antonios Karanasos and Christodoulos Stefanadis
Affiliation:
Keywords: Bare metal stents, restenosis, pathology, inflammation, biomarkers, CRP, interleukins, monocytes.
Abstract: Adverse reactions to bare metal stent implantation include stent thrombosis and restenosis. Although thrombosis in bare metal stents seems mainly to be affected by procedural factors, restenosis is a more complex procedure involving mechanisms of tissue repair after vessel injury occurring during implantation. This procedure includes early platelet and leukocyte invasion, followed by smooth muscle cell proliferation, as well as further inflammatory cell recruitment mediated by expression of chemokines and leukocyte activation at the site of the injury. In this report, we will focus on the role of inflammation in the development of in-stent restenosis in bare metal stents. In particular, we will describe the pathologic evidence implicating inflammatory cell involvement in the development of restenosis in animal and human models; we will analyze the molecular mechanisms linking inflammation with restenosis; and will review the association of pre-existing or procedure-induced systemic inflammation with adverse reactions at follow-up.
Export Options
About this article
Cite this article as:
Toutouzas Konstantinos, Karanasos Antonios and Stefanadis Christodoulos, Inflammatory Mechanisms of Adverse Reactions to BMS, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040002
DOI https://dx.doi.org/10.2174/1570161111311040002 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Galanin: A Novel Therapeutic Target for Depression, Anxiety Disorders and Drug Addiction?
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Mitochondrial and Metabolism: Novel Targets for Heart Failure)
Current Pharmaceutical Design Negative Correlation between Neuregulin-4 and IL-9 Serum Levels in Patients with Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Editorial [Hot Topic: Therapeutic Angiogenesis and Regeneration in Cardiovascular Diseases (Executive Editor: Masafumi Takahashi)]
Current Pharmaceutical Design Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction
Current Protein & Peptide Science GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges
Current Drug Targets Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Effects of Intravenous Apo A-I, HDLs and Apo A-I/Phospholipid Discs on Vascular Metabolism and Atherosclerosis in Animals and Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Medicinal Properties of Mangiferin, Structural Features, Derivative Synthesis, Pharmacokinetics and Biological Activities
Mini-Reviews in Medicinal Chemistry Dabigatran: The Anticoagulant We have Long Expected?
Recent Patents on Cardiovascular Drug Discovery Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond
Current Pharmaceutical Design